CL2011002234A1 - Uso de (s)-n-(3,4-difluoro-2-(2-fluoro-4-iodofenilamino)-6-metoxifenil)-1-(2,3-dihidroxipropil)ciclopropano-1-sulfonamida o n-(4-(2-fluoro-4-iodofenilamino)-1,5-dimetil-6-oxo-1,6-dihidroxipiridin-3-il)ciclopropanosulfonamida o un polimorfo o una sal de estos compuestos, para el tratamiento de cancer de pancreas. - Google Patents

Uso de (s)-n-(3,4-difluoro-2-(2-fluoro-4-iodofenilamino)-6-metoxifenil)-1-(2,3-dihidroxipropil)ciclopropano-1-sulfonamida o n-(4-(2-fluoro-4-iodofenilamino)-1,5-dimetil-6-oxo-1,6-dihidroxipiridin-3-il)ciclopropanosulfonamida o un polimorfo o una sal de estos compuestos, para el tratamiento de cancer de pancreas.

Info

Publication number
CL2011002234A1
CL2011002234A1 CL2011002234A CL2011002234A CL2011002234A1 CL 2011002234 A1 CL2011002234 A1 CL 2011002234A1 CL 2011002234 A CL2011002234 A CL 2011002234A CL 2011002234 A CL2011002234 A CL 2011002234A CL 2011002234 A1 CL2011002234 A1 CL 2011002234A1
Authority
CL
Chile
Prior art keywords
iodophenylamino
fluoro
treatment
dihydroxypyridin
cyclopropanesulfonamide
Prior art date
Application number
CL2011002234A
Other languages
English (en)
Inventor
Mark S Chapman
Original Assignee
Ardea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42129806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011002234(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc
Publication of CL2011002234A1 publication Critical patent/CL2011002234A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Uso de (s)-n-(3,4-difluoro-2-(2-fluoro-4-iodofenilamino)-6-metoxifenil)-1-(2,3-dihidroxipropil)ciclopropano-1-sulfonamida o n-(4-(2-fluoro-4-iodofenilamino)-1,5-dimetil-6-oxo-1,6-dihidroxipiridin-3-il)ciclopropanosulfonamida o un polimorfo o una sal de estos compuestos, para el tratamiento de cáncer de páncreas; y método de tratamiento.
CL2011002234A 2009-03-11 2011-09-09 Uso de (s)-n-(3,4-difluoro-2-(2-fluoro-4-iodofenilamino)-6-metoxifenil)-1-(2,3-dihidroxipropil)ciclopropano-1-sulfonamida o n-(4-(2-fluoro-4-iodofenilamino)-1,5-dimetil-6-oxo-1,6-dihidroxipiridin-3-il)ciclopropanosulfonamida o un polimorfo o una sal de estos compuestos, para el tratamiento de cancer de pancreas. CL2011002234A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15939709P 2009-03-11 2009-03-11

Publications (1)

Publication Number Publication Date
CL2011002234A1 true CL2011002234A1 (es) 2012-01-27

Family

ID=42129806

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002234A CL2011002234A1 (es) 2009-03-11 2011-09-09 Uso de (s)-n-(3,4-difluoro-2-(2-fluoro-4-iodofenilamino)-6-metoxifenil)-1-(2,3-dihidroxipropil)ciclopropano-1-sulfonamida o n-(4-(2-fluoro-4-iodofenilamino)-1,5-dimetil-6-oxo-1,6-dihidroxipiridin-3-il)ciclopropanosulfonamida o un polimorfo o una sal de estos compuestos, para el tratamiento de cancer de pancreas.

Country Status (20)

Country Link
US (1) US20120053211A1 (es)
EP (1) EP2405907A1 (es)
JP (1) JP2012520319A (es)
KR (1) KR20110128916A (es)
CN (1) CN102438609A (es)
AU (1) AU2010224108A1 (es)
BR (1) BRPI1009435A2 (es)
CA (1) CA2754891A1 (es)
CL (1) CL2011002234A1 (es)
CR (1) CR20110478A (es)
EA (1) EA201101305A1 (es)
IL (1) IL215037A0 (es)
MA (1) MA33109B1 (es)
MX (1) MX2011009494A (es)
SG (1) SG174271A1 (es)
SV (1) SV2011004017A (es)
TN (1) TN2011000456A1 (es)
TW (1) TW201100081A (es)
UY (1) UY32486A (es)
WO (1) WO2010105082A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2496575B1 (en) 2009-11-04 2014-04-30 Novartis AG Heterocyclic sulfonamide derivatives useful as mek inhibitors
WO2014071183A1 (en) 2012-11-02 2014-05-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor
CN103267852B (zh) * 2013-05-15 2015-03-25 中国医学科学院北京协和医院 成纤维激活蛋白α在制备胰腺癌预后试剂盒中的用途
KR101980809B1 (ko) * 2017-09-29 2019-05-21 대한민국 귀리껍질 추출물을 포함하는 췌장암의 예방 또는 치료용 약학적 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9022A (en) * 1852-06-15 Organ
US8005A (en) * 1851-04-01 He ne y bo o t
US8101799B2 (en) * 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
CA2649122C (en) * 2006-04-18 2015-06-30 Ardea Biosciences, Inc. Pyridone sulfonamides and pyridone sulfamides as mek inhibitors
MX2010001244A (es) * 2007-07-30 2010-08-31 Ardea Biosciences Inc Derivados de n-(arilamino) sulfonamidas que incluyen polimorfos como inhibidores de mek asi como composiciones, metodos de uso y de preparacion de los mismos.
US8044240B2 (en) * 2008-03-06 2011-10-25 Ardea Biosciences Inc. Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof

Also Published As

Publication number Publication date
AU2010224108A1 (en) 2011-09-22
EA201101305A1 (ru) 2012-04-30
MA33109B1 (fr) 2012-03-01
IL215037A0 (en) 2011-11-30
BRPI1009435A2 (pt) 2016-03-01
TW201100081A (en) 2011-01-01
US20120053211A1 (en) 2012-03-01
SV2011004017A (es) 2012-01-06
UY32486A (es) 2010-10-29
JP2012520319A (ja) 2012-09-06
WO2010105082A1 (en) 2010-09-16
CR20110478A (es) 2011-10-24
MX2011009494A (es) 2011-10-11
CN102438609A (zh) 2012-05-02
EP2405907A1 (en) 2012-01-18
SG174271A1 (en) 2011-10-28
TN2011000456A1 (en) 2013-03-27
KR20110128916A (ko) 2011-11-30
CA2754891A1 (en) 2010-09-16

Similar Documents

Publication Publication Date Title
CY1117615T1 (el) Ενωσεις θειαζολης σουλφοναμιδης και οξαζολης
CY1122983T1 (el) Νεες ενωσεις
CY1120619T1 (el) Χημικες οντοτητες
CL2013001381A1 (es) Compuestos derivados de hidroxi-amida pirimidina, inhibidores de la proteina deacetilasa hdac6; composicion farmaceutica; combinación farmaceutica; metodos de uso para el tratamiento de una enfermedad proliferativa o cancer; un kit
EA201170872A1 (ru) Ингибиторы протеинкиназы
PE20141824A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
CL2017002090A1 (es) Inhibidores selectivos de bace1
EA200970935A1 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
BR112014003237A2 (pt) compostos de indazol, composições e métodos de uso
DK1928438T3 (da) Anvendelse af ibudilast til behandling af stofafhængighed
ECSP12011799A (es) Compuestos de espiropiperidina y uso farmacéutico de los mismos
EA200900781A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды
EA201100424A1 (ru) Новые ингибиторы
CL2008002295A1 (es) Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
EA201270590A1 (ru) Ингибиторы акт
LTC1912640I2 (lt) HDAC inhibitoriaus panobinostato panaudojimas mielomos gydymui
CU23779B7 (es) Compuestos de pirazolina y su uso y composiciones farmacéuticas
GT200900065A (es) Derivado de 2-piridincarboxamida que tiene efecto activador de gk
CL2013002820A1 (es) Compuestos derivados de cefalosporinas, un profarmaco, un hidrato, un solvato, un isomero o una sal; composiciones farmaceuticas de estos; y un metodo para un tratamiento antibiotico.
CY1120355T1 (el) Αναστολεις toy iap
CL2011002233A1 (es) Metodo para tratar o prevenir el cancer, que comprende administrar una combinacion farmaceutica sinergica de: a) (s)-n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)-6-metoxifenil)-1-(2,3-dihidroxipropil)ciclopropan-1-sulfonamida y b) 3-(6,7-bis(2-metoxietoxi)quinazolin-4-ilamino)benzonitrilo; composicion farmaceutica; y kit farmaceutico.
CO6361988A2 (es) Forma cristalina de un compuesto de 4-[2-(2-fluorofenoximetil)fenil]piperidina.
ECSP10010145A (es) Uso de 3,11b-cis-dihidrotetrabenazina en el tratamiento de la esclerosis múltiple y la mielitis autoinmunitaria
CL2011002234A1 (es) Uso de (s)-n-(3,4-difluoro-2-(2-fluoro-4-iodofenilamino)-6-metoxifenil)-1-(2,3-dihidroxipropil)ciclopropano-1-sulfonamida o n-(4-(2-fluoro-4-iodofenilamino)-1,5-dimetil-6-oxo-1,6-dihidroxipiridin-3-il)ciclopropanosulfonamida o un polimorfo o una sal de estos compuestos, para el tratamiento de cancer de pancreas.